Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
Nutriband Inc. (NASDAQ:NTRB) has achieved a significant milestone with its inclusion in four Russell indexes: the Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index, and Russell 3000E Growth Index as part of the 2025 Russell indexes reconstitution.
CEO Gareth Sheridan highlighted the company's AVERSA pipeline development, particularly AVERSA Fentanyl, which has a projected peak annual US sales potential of $80 million to $200 million. The company aims to enhance the safety profile of easily abused medications while ensuring availability to patients in need.
The Russell indexes, which serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. FTSE Russell will transition to a semi-annual reconstitution frequency starting in 2026.
Nutriband Inc. (NASDAQ:NTRB) ha raggiunto un traguardo importante con l'inserimento in quattro indici Russell: il Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index e Russell 3000E Growth Index, nell'ambito della ricostituzione degli indici Russell 2025.
Il CEO Gareth Sheridan ha sottolineato lo sviluppo della pipeline AVERSA dell'azienda, in particolare AVERSA Fentanyl, che ha un potenziale di vendite annuali negli USA stimato tra 80 e 200 milioni di dollari. L'azienda punta a migliorare il profilo di sicurezza di farmaci facilmente soggetti ad abuso, garantendo al contempo la disponibilità per i pazienti che ne hanno bisogno.
Gli indici Russell, che rappresentano benchmark per circa 10,6 trilioni di dollari di asset a giugno 2024, sono ampiamente utilizzati da gestori di investimenti e investitori istituzionali per fondi indicizzati e strategie di investimento attive. FTSE Russell passerà a una frequenza di ricostituzione semestrale a partire dal 2026.
Nutriband Inc. (NASDAQ:NTRB) ha alcanzado un hito importante al ser incluida en cuatro índices Russell: el Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index y Russell 3000E Growth Index, como parte de la reconstitución de los índices Russell 2025.
El CEO Gareth Sheridan destacó el desarrollo de la cartera AVERSA de la compañía, en particular AVERSA Fentanyl, que tiene un potencial de ventas anuales máximas en EE.UU. estimado entre 80 y 200 millones de dólares. La empresa busca mejorar el perfil de seguridad de medicamentos propensos al abuso, asegurando al mismo tiempo su disponibilidad para los pacientes que lo necesitan.
Los índices Russell, que sirven como referencia para aproximadamente 10,6 billones de dólares en activos a junio de 2024, son ampliamente utilizados por gestores de inversión e inversores institucionales para fondos indexados y estrategias activas. FTSE Russell pasará a una frecuencia de reconstitución semestral a partir de 2026.
Nutriband Inc. (NASDAQ:NTRB)는 2025년 러셀 지수 재구성의 일환으로 러셀 마이크로캡 지수, 러셀 마이크로캡 성장 지수, 러셀 3000E 지수, 러셀 3000E 성장 지수 등 네 개의 러셀 지수에 포함되는 중요한 이정표를 달성했습니다.
CEO Gareth Sheridan는 회사의 AVERSA 파이프라인 개발, 특히 AVERSA 펜타닐에 대해 강조했으며, 이는 미국 내 연간 최대 매출 잠재력이 8천만 달러에서 2억 달러 사이로 예상됩니다. 회사는 남용이 쉬운 약물의 안전성을 향상시키면서도 필요한 환자들에게 약물 공급을 보장하는 것을 목표로 하고 있습니다.
러셀 지수는 2024년 6월 기준 약 10.6조 달러 규모의 자산에 대한 벤치마크 역할을 하며, 투자 관리자와 기관 투자자들이 인덱스 펀드 및 적극적인 투자 전략에 널리 활용하고 있습니다. FTSE 러셀은 2026년부터 반기별 재구성 빈도로 전환할 예정입니다.
Nutriband Inc. (NASDAQ:NTRB) a franchi une étape importante en étant inclus dans quatre indices Russell : le Russell Microcap Index, le Russell Microcap Growth Index, le Russell 3000E Index et le Russell 3000E Growth Index, dans le cadre de la reconstitution des indices Russell 2025.
Le PDG Gareth Sheridan a mis en avant le développement de la pipeline AVERSA de la société, notamment AVERSA Fentanyl, qui présente un potentiel de ventes annuelles maximales aux États-Unis estimé entre 80 et 200 millions de dollars. L'entreprise vise à améliorer le profil de sécurité des médicaments facilement abusés tout en garantissant leur disponibilité aux patients dans le besoin.
Les indices Russell, qui servent de référence pour environ 10,6 billions de dollars d'actifs en juin 2024, sont largement utilisés par les gestionnaires d'investissement et les investisseurs institutionnels pour les fonds indiciels et les stratégies d'investissement actives. FTSE Russell passera à une fréquence de reconstitution semi-annuelle à partir de 2026.
Nutriband Inc. (NASDAQ:NTRB) hat einen bedeutenden Meilenstein erreicht, indem es in vier Russell-Indizes aufgenommen wurde: den Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index und Russell 3000E Growth Index im Rahmen der Russell-Index-Neuaufstellung 2025.
CEO Gareth Sheridan hob die Entwicklung der AVERSA-Pipeline des Unternehmens hervor, insbesondere AVERSA Fentanyl, das ein geschätztes maximales jährliches US-Verkaufspotenzial von 80 bis 200 Millionen US-Dollar aufweist. Das Unternehmen verfolgt das Ziel, die Sicherheitsprofile von leicht missbrauchbaren Medikamenten zu verbessern und gleichzeitig die Verfügbarkeit für bedürftige Patienten sicherzustellen.
Die Russell-Indizes dienen als Benchmarks für etwa 10,6 Billionen US-Dollar an Vermögenswerten per Juni 2024 und werden von Investmentmanagern und institutionellen Anlegern häufig für Indexfonds und aktive Anlagestrategien genutzt. FTSE Russell wird ab 2026 auf eine halbjährliche Neugewichtung umstellen.
- Addition to four prestigious Russell indexes enhances visibility and institutional credibility
- AVERSA Fentanyl projected peak annual US sales potential of $80-200 million
- Inclusion in indexes reflects growing market recognition and momentum
- None.
Insights
Nutriband's inclusion in Russell indexes increases visibility and passive investment inflows, signaling market recognition of AVERSA's potential.
Nutriband's addition to multiple Russell indexes represents a significant milestone for the company's market visibility. This inclusion in the Russell Microcap, Microcap Growth, 3000E, and 3000E Growth Indexes will likely trigger automatic buying from passive funds tracking these benchmarks, potentially providing share price support.
The Russell indexes are tracked by funds managing approximately $10.6 trillion in assets, meaning even small allocations can drive meaningful capital flows toward Nutriband. This institutional recognition typically leads to increased trading liquidity and broader market awareness.
Most revealing is management's highlighting of their AVERSA Fentanyl product, which they project could achieve $80-200 million in peak annual US sales. This significant revenue potential relative to Nutriband's microcap status explains the company's inclusion in growth-oriented indexes.
Index inclusion doesn't directly affect fundamentals but creates a virtuous cycle of visibility: greater institutional coverage leads to increased investor interest, potentially improving access to capital. For microcap companies like Nutriband, developing pharmaceutical products requiring substantial R&D investment, this improved capital access pathway is particularly valuable.
The semi-annual reconstitution frequency starting in 2026 means Nutriband must maintain qualifying metrics to retain its positions in these indexes, adding accountability pressure on management to execute their AVERSA pipeline development strategy.
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes, as part of the 2025 Russell indexes reconstitution.
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“Being added to the four Russell indexes is a great honor for us as a company as we continue to strive towards building shareholder value and progressing the development of our AVERSA pipeline and in particular AVERSA Fentanyl which has the potential to reach peak annual US sales of
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell’s US indexes serve as the benchmark for about
Fiona Bassett, CEO of FTSE Russell, An LSEG business, comments:
“The Russell indexes have continuously adapted to the evolving dynamic US economy, and it’s crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.”
For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What Russell indexes was Nutriband (NTRB) added to in 2025?
What is the projected peak annual US sales potential for Nutriband's AVERSA Fentanyl?
How much in assets do the Russell US indexes benchmark?
What changes are coming to the Russell indexes reconstitution schedule?
What is Nutriband's main product development focus?
